Plaque Psoriasis

Also known as: Psoriasis, Plaque-type / Psoriasis Vulgaris (Plaque Psoriasis) / Psoriasis, Plaque-type Psoriasis / Plaque-Type Psoriasis / Plaque Type Psoriasis / Psoriasis Vulgaris / Plaque Psoriasis Vulgaris / Vulgaris Psoriasis / Nummular psoriasis / Psoriasis

DrugDrug NameDrug Description
DB02300CalcipotriolCalcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
DB00136CalcitriolCalcitriol or 1,25-dihydroxycholecalciferol (abbreviated 1,25-(OH)2-D3) is the active form of vitamin D found in the body (vitamin D3). Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis). It is produced in the kidneys via 25-hydroxyvitamin D-1 α-hydroxylase by conversion from 25-hydroxycholecalciferol (calcidiol). This is stimulated by a decrease in serum calcium, phosphate (PO43−) and parathyroid hormone (PTH) levels. It regulates calcium levels by increasing the absorption of calcium and phosphate from the gastrointestinal tract, increasing calcium and phosphate reabsorption in the kidneys and inhibiting the release of PTH. Calcitriol is also commonly used as a medication in the treatment of hypocalcemia and osteoporosis.
DB00547DesoximetasoneA topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc. [PubChem]
DB00005EtanerceptDimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.
DB00065InfliximabInfliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469]. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α [A106], infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α [A106]. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis [FDA Label]. In clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to alternative first-line therapies for that disorder [ FDA Label]. There are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. They are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.
DB00799TazaroteneTazarotene (marketed as Tazorac®, Avage® and Zorac®) is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). [Wikipedia]
DrugDrug NameTargetType
DB02300CalcipotriolVitamin D3 receptortarget
DB02300CalcipotriolMyeloperoxidaseenzyme
DB02300Calcipotriol1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB00136CalcitriolVitamin D3 receptortarget
DB00136Calcitriol1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB00136CalcitriolCytochrome P450 3A4enzyme
DB00136CalcitriolHomeobox protein Hox-A10target
DB00136CalcitriolVitamin D-binding proteintarget
DB00547DesoximetasoneGlucocorticoid receptortarget
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB00065InfliximabTumor necrosis factortarget
DB00799TazaroteneRetinoic acid receptor alphatarget
DB00799TazaroteneRetinoic acid receptor RXR-betatarget
DB00799TazaroteneRetinoic acid receptor gammatarget
DB00799TazaroteneRetinoic acid receptor betatarget
DB00799TazaroteneCytochrome P450 2C8enzyme
DrugDrug NamePhaseStatusCount
DB00033Interferon gamma-1b0Terminated1
DB01281Abatacept1Completed2
DB00443Betamethasone1Completed5
DB00083Botulinum Toxin Type A1Completed1
DB02300Calcipotriol1Completed5
DB00136Calcitriol1Completed1
DB01013Clobetasol propionate1Completed2
DB00095Efalizumab1Completed1
DB00591Fluocinolone acetonide1Completed1
DB00741Hydrocortisone1Completed1
DB13029MK-08731Completed2
DB00683Midazolam1Terminated1
DB00764Mometasone1Completed1
DB06589Pazopanib1Completed1
DB09153Sodium Chloride1Completed1
DB02300Calcipotriol1 / 2Completed1
DB00005Etanercept1 / 2Not Yet Recruiting1
DB12091Gadolinium1 / 2Not Yet Recruiting1
DB00789Gadopentetic acid1 / 2Not Yet Recruiting1
DB09029Secukinumab1 / 2Completed1
DB12187Abacavir hydroxyacetate2Completed1
DB01281Abatacept2Completed1
DB00459Acitretin2Recruiting1
DB05676Apremilast2Completed2
DB05676Apremilast2Not Yet Recruiting1
DB00443Betamethasone2Completed2
DB02300Calcipotriol2Completed6
DB00136Calcitriol2Completed1
DB11121Chloroxylenol2Terminated1
DB08908Dimethyl fumarate2Completed1
DB11687E-62012Completed1
DB12154Itacitinib2Completed1
DB01026Ketoconazole2Unknown Status1
DB00563Methotrexate2Recruiting1
DB00764Mometasone2Completed1
DB00764Mometasone2Suspended1
DB06380Namilumab2Completed1
DB00540Nortriptyline2Completed2
DB11786Pefcalcitol2Completed2
DB05511Piclidenoson2Completed1
DB12016Ponesimod2Completed1
DB01656Roflumilast2Withdrawn1
DB08877Ruxolitinib2Completed1
DB09029Secukinumab2Completed2
DB06371Siplizumab2Completed1
DB01041Thalidomide2Completed1
DB00596Ulobetasol2Completed1
DB00596Ulobetasol2Withdrawn1
DB05511Piclidenoson2 / 3Completed1
DB00051Adalimumab3Completed6
DB00051Adalimumab3Recruiting1
DB05676Apremilast3Completed2
DB05676Apremilast3Not Yet Recruiting1
DB00443Betamethasone3Completed3
DB00443Betamethasone3Recruiting1
DB05459Briakinumab3Completed2
DB11776Brodalumab3Completed1
DB02300Calcipotriol3Completed3
DB08904Certolizumab pegol3Active Not Recruiting3
DB00169Cholecalciferol3Completed1
DB08908Dimethyl fumarate3Withdrawn1
DB01613Erythrityl Tetranitrate3Active Not Recruiting1
DB00005Etanercept3Active Not Recruiting2
DB00005Etanercept3Completed3
DB00005Etanercept3Recruiting1
DB00005Etanercept3Withdrawn1
DB01677Fumaric Acid3Completed1
DB00741Hydrocortisone3Completed1
DB00065Infliximab3Completed1
DB11569Ixekizumab3Completed4
DB11569Ixekizumab3Recruiting2
DB00563Methotrexate3Completed3
DB11786Pefcalcitol3Completed1
DB05511Piclidenoson3Not Yet Recruiting1
DB09029Secukinumab3Active Not Recruiting1
DB09029Secukinumab3Completed4
DB13689Tacalcitol3Completed1
DB00799Tazarotene3Completed3
DB00799Tazarotene3Recruiting2
DB14004Tildrakizumab3Active Not Recruiting2
DB14004Tildrakizumab3Withdrawn1
DB00596Ulobetasol3Completed1
DB00596Ulobetasol3Recruiting2
DB05679Ustekinumab3Completed2
DB09145Water3Completed1
DB00459Acitretin4Unknown Status1
DB00459Acitretin4Withdrawn1
DB00051Adalimumab4Completed1
DB00092Alefacept4Completed1
DB05676Apremilast4Completed1
DB05676Apremilast4Enrolling by Invitation1
DB05676Apremilast4Not Yet Recruiting1
DB05676Apremilast4Recruiting2
DB00443Betamethasone4Completed2
DB00443Betamethasone4Recruiting2
DB00443Betamethasone4Terminated1
DB11776Brodalumab4Recruiting1
DB02300Calcipotriol4Completed3
DB02300Calcipotriol4Recruiting2
DB02300Calcipotriol4Terminated1
DB00136Calcitriol4Active Not Recruiting1
DB01013Clobetasol propionate4Completed5
DB00547Desoximetasone4Recruiting1
DB00095Efalizumab4Completed1
DB00095Efalizumab4Terminated1
DB00005Etanercept4Completed7
DB00005Etanercept4Withdrawn1
DB11834Guselkumab4Not Yet Recruiting1
DB11569Ixekizumab4Not Yet Recruiting1
DB00563Methotrexate4Not Yet Recruiting1
DB09029Secukinumab4Completed1
DB09029Secukinumab4Recruiting3
DB05679Ustekinumab4Completed1
DB05679Ustekinumab4Unknown Status1
DB09145Water4Completed1
DB00443BetamethasoneNot AvailableCompleted1
DB00443BetamethasoneNot AvailableRecruiting1
DB02300CalcipotriolNot AvailableCompleted1
DB02300CalcipotriolNot AvailableRecruiting1
DB00153ErgocalciferolNot AvailableCompleted1
DB00005EtanerceptNot AvailableCompleted1
DB12379IndirubinNot AvailableUnknown Status1
DB09029SecukinumabNot AvailableRecruiting1
DB00864TacrolimusNot AvailableCompleted1
DB00799TazaroteneNot AvailableSuspended1
DB11094Vitamin DNot AvailableCompleted1